Prospective Grant of Exclusive License: The Development of MRI-1569, MRI-2213 and MRI-2214 as a Therapeutic To Treat Obesity, Diabetes, Fatty Liver Disease and Liver Fibrosis, 22997-22998 [2016-08986]
Download as PDF
<![CDATA[
Federal Register / Vol. 81, No. 75 / Tuesday, April 19, 2016 / Notices
Bethesda, MD 20892–2542, (301) 594–8898,
barnardm@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
MSC 7892, Bethesda, MD 20892, 301–435–
2902, filpuladr@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: April 13, 2016.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
Dated: April 13, 2016.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–08991 Filed 4–18–16; 8:45 am]
[FR Doc. 2016–08996 Filed 4–18–16; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
mstockstill on DSK4VPTVN1PROD with NOTICES
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Great
Challenge Synthetic Biology Program Project.
Date: May 19–20, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sergei Ruvinov, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4158,
MSC 7806, Bethesda, MD 20892, 301–435–
1180, ruvinser@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
High Throughput Screening.
Date: May 19, 2016.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: David Filpula, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6181,
VerDate Sep<11>2014
18:02 Apr 18, 2016
Jkt 238001
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; ‘‘NIAID Investigator
Initiated Program Project Applications (P01)’’
Date: May 12, 2016.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Room
3F100, 5601 Fishers Lane, Rockville, MD
20892, (Telephone Conference Call).
Contact Person: Jay R. Radke, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room #3G11B, National Institutes of Health,
NIAID, 5601 Fishers Lane MSC–9823,
Bethesda, MD 20892–9823, (240) 669–5046,
jay.radke@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: April 14, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–08993 Filed 4–18–16; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
22997
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel; NIBIB P41 Site Visit
(2016/10).
Date: May 1–3, 2016.
Time: 6:00 p.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Dallas Marriott Suites Medical/
Market Center, 2493 North Stemmons
Freeway, Dallas, TX 75207.
Contact Person: Ruixia Zhou, Ph.D.,
Scientific Review Officer, 6707 Democracy
Boulevard, Democracy Two Building, Suite
967, Bethesda, MD 20892, (301) 496–4773,
zhour@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Dated: April 13, 2016.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–08994 Filed 4–18–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: The Development of MRI–
1569, MRI–2213 and MRI–2214 as a
Therapeutic To Treat Obesity,
Diabetes, Fatty Liver Disease and Liver
Fibrosis
National Institutes of Diabetes
and Digestive and Kidney Diseases,
Public Health Service, PHS, National
Institutes of Health, Department of
Health and Human Services.
AGENCY:
E:\FR\FM\19APN1.SGM
19APN1
22998
ACTION:
Federal Register / Vol. 81, No. 75 / Tuesday, April 19, 2016 / Notices
Notice.
This notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
part 404.7, that the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an exclusive patent license to
practice the following inventions
embodied in the following patent
applications, entitled ‘‘CB1 receptor
mediating compounds’’:
1. U.S. Provisional Patent Application
No.: 61/991,333, HHS Ref. No.: E–
140–2014/0–US–01, Filed: May 09,
2014.
2. PCT Application No.: PCT/US2015/
029946, HHS Ref. No.: E–140–2014/
0–PCT–02, Filed: May 08, 2015.
3. U.S. Provisional Patent Application
No.: 61/725,949, HHS Ref. No.: E–
282–2012/0–US–01, Filed:
November 13, 2012.
4. PCT Application No.: PCT/US2013/
069686, HHS Ref. No.: E–282–2012/
0–PCT–02, Filed: November 12,
2013.
5. U.S. Patent Application No.: 14/
442,383, HHS Ref. No.: E–282–
2012/0–US–03, Filed: May 12,
2015.
6. Canadian Patent Application No.:
2889697, HHS Ref. No.: E–282–
2012/0–CA–04, Filed: April 27,
2015.
7. European Patent Application No.:
13802153.0, HHS Ref. No.: E–282–
2012/0–EP–05, Filed: June 01, 2015.
8. Indian Patent Application No.: 3733/
DELNP/2015, HHS Ref. No.: E–282–
2012/0–IN–06, Filed: May 01, 2015.
9. Japanese Patent Application No.:
2015–542015, HHS Ref. No.: E–
282–2012/0–JP–07, Filed: May 11,
2015.
10. Chinese Patent Application No.:
201380069389.9, HHS Ref. No.: E–
282–2012/0–CN–08, Filed: July 3,
2015.
11. US Provisional Application No.: 62/
171,179, HHS Ref. No.: E–282–
2012/1–US–01, Filed: June 04,
2015.
to Kalytera Therapeutics Inc.,
(‘‘Kalytera’’), a company incorporated
under the laws of Delaware and having
an office in Hermosa Beach, California.
The patent rights in these inventions
have been assigned to the United States
of America. This license may be
worldwide. The field of use may be
limited to the use of the Licensed Patent
Rights to the development of select
compounds from the patents listed
above.
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
Only written comments and/or
applications for a license which are
received by the Technology
DATES:
VerDate Sep<11>2014
18:02 Apr 18, 2016
Jkt 238001
Advancement Office, The National
Institute of Diabetes and Digestive and
Kidney Diseases on or before May 4,
2016 will be considered.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Requests for copies of the
patent application, patents, inquiries,
comments, and other materials relating
to the contemplated exclusive license
should be directed to: Betty Tong, Ph.D.,
Sr. Licensing and Patenting Manager,
Technology Advancement Office, The
National Institute of Diabetes and
Digestive and Kidney Diseases, 12A
South Drive, Bethesda, MD 20892;
Email: betty.tong@nih.gov. A signed
confidentiality non-disclosure
agreement will be required to receive
copies of any patent applications that
have not been published by the United
States Patent and Trademark Office or
the World Intellectual Property
Organization.
National Center for Advancing
Translational Sciences; Notice of
Meetings
ADDRESSES:
This
technology, and its corresponding
patent applications, is directed to
methods of treating fibrosis, obesity and
associated diseases such as type 2
diabetes by administering an agent that
reduces appetite, body weight, hepatic
steatosis, and insulin resistance. This
technology may be useful as a means for
treating various fibrotic diseases and
metabolic syndromes without serious
adverse neuropsychiatric side effects.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR part 404.7. The
prospective exclusive license may be
granted unless within fifteen (15) days
from the date of this published notice,
the Technology Advancement Office
receives written evidence and argument
that establishes that the grant of the
license would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.7.
Properly filed competing applications
for a license in response to this notice
will be treated as objections to the
contemplated license. Comments and
objections submitted in response to this
notice will not be made available for
public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
SUPPLEMENTARY INFORMATION:
Dated: April 13, 2016.
Anna Amar,
Acting Deputy Director, Technology
Advancement Office, National Institute of
Diabetes and Digestive and Kidney Diseases,
National Institutes of Health.
[FR Doc. 2016–08986 Filed 4–18–16; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of meetings of the National
Center for Advancing Translational
Sciences.
The meetings will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Cures Acceleration
Network Review Board.
Date: May 12, 2016.
Time: 8:30 a.m. to 2:45 p.m.
Agenda: Report from the Institute Director.
Place: National Institutes of Health,
Building 31, Conference Room 10, 31 Center
Drive, Bethesda, MD 20892.
Contact Person: Anna L. Ramsey-Ewing,
Ph.D., Executive Secretary, National Center
for Advancing Translational Sciences, 1
Democracy Plaza, Room 1072, Bethesda, MD
20892, 301–435–0809, anna.ramseyewing@
nih.gov.
Name of Committee: National Center for
Advancing Translational Sciences Advisory
Council.
Date: May 12, 2016.
Open: 8:30 a.m. to 2:45 p.m.
Agenda: Report from the Institute Director
and other staff.
Place: National Institutes of Health,
Building 31, Conference Room 10, 31 Center
Drive, Bethesda, MD 20892.
Closed: 3:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, Conference Room 10, 31 Center
Drive, Bethesda, MD 20892.
Contact Person: Anna L. Ramsey-Ewing,
Ph.D., Executive Secretary, National Center
for Advancing Translational Sciences, 1
Democracy Plaza, Room 1072, Bethesda, MD
20892, 301–435–0809, anna.ramseyewing@
nih.gov.
E:\FR\FM\19APN1.SGM
19APN1
]]>Agencies
[Federal Register Volume 81, Number 75 (Tuesday, April 19, 2016)]
[Notices]
[Pages 22997-22998]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-08986]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: The Development of MRI-
1569, MRI-2213 and MRI-2214 as a Therapeutic To Treat Obesity,
Diabetes, Fatty Liver Disease and Liver Fibrosis
AGENCY: National Institutes of Diabetes and Digestive and Kidney
Diseases, Public Health Service, PHS, National Institutes of Health,
Department of Health and Human Services.
[[Page 22998]]
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR
part 404.7, that the National Institutes of Health, Department of
Health and Human Services, is contemplating the grant of an exclusive
patent license to practice the following inventions embodied in the
following patent applications, entitled ``CB1 receptor mediating
compounds'':
1. U.S. Provisional Patent Application No.: 61/991,333, HHS Ref. No.:
E-140-2014/0-US-01, Filed: May 09, 2014.
2. PCT Application No.: PCT/US2015/029946, HHS Ref. No.: E-140-2014/0-
PCT-02, Filed: May 08, 2015.
3. U.S. Provisional Patent Application No.: 61/725,949, HHS Ref. No.:
E-282-2012/0-US-01, Filed: November 13, 2012.
4. PCT Application No.: PCT/US2013/069686, HHS Ref. No.: E-282-2012/0-
PCT-02, Filed: November 12, 2013.
5. U.S. Patent Application No.: 14/442,383, HHS Ref. No.: E-282-2012/0-
US-03, Filed: May 12, 2015.
6. Canadian Patent Application No.: 2889697, HHS Ref. No.: E-282-2012/
0-CA-04, Filed: April 27, 2015.
7. European Patent Application No.: 13802153.0, HHS Ref. No.: E-282-
2012/0-EP-05, Filed: June 01, 2015.
8. Indian Patent Application No.: 3733/DELNP/2015, HHS Ref. No.: E-282-
2012/0-IN-06, Filed: May 01, 2015.
9. Japanese Patent Application No.: 2015-542015, HHS Ref. No.: E-282-
2012/0-JP-07, Filed: May 11, 2015.
10. Chinese Patent Application No.: 201380069389.9, HHS Ref. No.: E-
282-2012/0-CN-08, Filed: July 3, 2015.
11. US Provisional Application No.: 62/171,179, HHS Ref. No.: E-282-
2012/1-US-01, Filed: June 04, 2015.
to Kalytera Therapeutics Inc., (``Kalytera''), a company incorporated
under the laws of Delaware and having an office in Hermosa Beach,
California. The patent rights in these inventions have been assigned to
the United States of America. This license may be worldwide. The field
of use may be limited to the use of the Licensed Patent Rights to the
development of select compounds from the patents listed above.
DATES: Only written comments and/or applications for a license which
are received by the Technology Advancement Office, The National
Institute of Diabetes and Digestive and Kidney Diseases on or before
May 4, 2016 will be considered.
ADDRESSES: Requests for copies of the patent application, patents,
inquiries, comments, and other materials relating to the contemplated
exclusive license should be directed to: Betty Tong, Ph.D., Sr.
Licensing and Patenting Manager, Technology Advancement Office, The
National Institute of Diabetes and Digestive and Kidney Diseases, 12A
South Drive, Bethesda, MD 20892; Email: betty.tong@nih.gov. A signed
confidentiality non-disclosure agreement will be required to receive
copies of any patent applications that have not been published by the
United States Patent and Trademark Office or the World Intellectual
Property Organization.
SUPPLEMENTARY INFORMATION: This technology, and its corresponding
patent applications, is directed to methods of treating fibrosis,
obesity and associated diseases such as type 2 diabetes by
administering an agent that reduces appetite, body weight, hepatic
steatosis, and insulin resistance. This technology may be useful as a
means for treating various fibrotic diseases and metabolic syndromes
without serious adverse neuropsychiatric side effects.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part
404.7. The prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the
Technology Advancement Office receives written evidence and argument
that establishes that the grant of the license would not be consistent
with the requirements of 35 U.S.C. 209 and 37 CFR part 404.7.
Properly filed competing applications for a license in response to
this notice will be treated as objections to the contemplated license.
Comments and objections submitted in response to this notice will not
be made available for public inspection and, to the extent permitted by
law, will not be released under the Freedom of Information Act, 5
U.S.C. 552.
Dated: April 13, 2016.
Anna Amar,
Acting Deputy Director, Technology Advancement Office, National
Institute of Diabetes and Digestive and Kidney Diseases, National
Institutes of Health.
[FR Doc. 2016-08986 Filed 4-18-16; 8:45 am]
BILLING CODE 4140-01-P
